Tin tức & Cập nhật

In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).

Smoking and occupational dust exposure appear to contribute to an increased risk of idiopathic pulmonary fibrosis (IPF), according to a study.

The human monoclonal antibody pamrevlumab fails to deliver benefit for patients with idiopathic pulmonary fibrosis (IPF) in the phase III ZEPHYRUS-1 trial.